おすすめツイート
#ASCO2025 was filled with groundbreaking science. Feeling inspired and grateful to be part of this community. These are just a few of the top breast cancer studies presented, and some of the remaining questions.
Practicing changing for patients with PV! Rusfertide has been very helpful reducing transfusions in patient with PV. It also improves in iron deficiency and fatigue. #ASCO #globaloncology #ASCO2025 #OncoAlertTOPTweet
Sacituzumab plus immunotherapy shows PFS. OS immature but trend for improvement. #ASCO2025 #BreastCancer #oncology #ASCENT
INOVA120 trial shows improvement in overall survival and continued PFS improvement #OncoAlertTopTweet #ASCO25 #BreastCancer #oncology
A wife has started this petition in honor of her husband, an intern who recently died by suicide. It asks for structural changes to the program. A look at this short list highlights how absurd and abusive medical training can be, and how far we have to go: change.org/p/chase-smith-…
Survival data on adjuvant paclitaxel and trastuzumab in node negative and HER2 positive cancer
NEW: In the final 10-year analysis of the APT trial of adjuvant paclitaxel and trastuzumab for node–, HER2+ breast cancer, 10-year invasive disease-free survival was 91·3% (95% CI 88·3–94·4) and breast cancer-specific survival was 98·8% (97·6–100). #bcsm thelancet.com/journals/lanon…
NEW: In the final 10-year analysis of the APT trial of adjuvant paclitaxel and trastuzumab for node–, HER2+ breast cancer, 10-year invasive disease-free survival was 91·3% (95% CI 88·3–94·4) and breast cancer-specific survival was 98·8% (97·6–100). #bcsm thelancet.com/journals/lanon…
🔥Advances in antibody-based therapy in oncology @NatureCancer doi.org/10.1038/s43018… 👏Amazing review 😅what you always wanted to know about antibodies in oncology, here it is explained.. ADCC, ADCP, Fc engineering, BiTEs, RICs, IO combo, ADC... @myESMO @OncoAlert @EASLedu
San Diego December 2022. Amazing sunset and La Jolla drive youtu.be/zB0hckGQPpI
youtube.com
YouTube
San Diego December 2022. Amazing sunset and La Jolla drive
1. #SABCS22 updates w/ @DrSGraff from @BrownUCancer on HR+ #breastcancer: - #TAM01 "BabyTam" - #EMERALD: Elacestrant - #CAPItello291: Capivasertib - #TROPiCS2: Sacituzumab Govitecan #bcsm #SABCSUpdate @OncoAlert @SoMeCME @SABCSSanAntonio
1/ #SABCSUpdate 📣 #OncTwitter: Clinically relevant updates on CDK4/6 inhibitors in HR+/HER2- advanced #breastcancer w/ @DrSGraff & @OncBrothers! Supported by educational grants from Gilead & Lilly. CME ℹ️ bit.ly/3Wk7Y7T 📊 What is your specialty❓
The investigational therapy pyrotinib plus chemotherapy improved outcomes for patients with pretreated HER2+ breast cancer in the phase III PHOEBE trial, the results of which were presented at #SABCS21. bit.ly/3DE6NGC
Much needed #SABCS2021
Roadmap for Early TNBC and for Metastatic TNBC by @hoperugo (thanks @ErikaHamilton9 and @DrSGraff for sharing). Amazing summary/algorithms that we can easily follow in our community settings #SABCS21 #bcsm
Finally!
.@OncoAlert @FDAOncology has approved abemaciclib for the adjuvant treatment of early stage breast cancer!! #bcsm #MonarchE @myESMO 🚨🚨🚨
Phase 2 non-randomized trial of 80 prev untreated pts w CLL who received ibrutinib/venetoclax x 24 cycles showed bone marrow-undetectable min residual disease (MRD) in 56% at 12 cycles, w 75% overall achieving undetectable MRD as best response, 3yr PFS 93% ja.ma/3AUT8tz
🧵Announcing this year's strategic initiative: #GiveHerAReasonToStay in Healthcare campaign! #WomenInMedicine👩🏿⚕️👩⚕️are leaving in droves due to gender #equity issues + #COVID19. We have an urgent need to keep our health system strong. Join us! Info: bit.ly/3xk57Pk 1/4
This year's strategic initiative that I developed for the Women's Leadership #CME course @HarvardMed to support #WomenInMedicine is #GiveHerAReasonToStay in Healthcare. Joined again by @AMWADoctors & @ELAMProgram😀 Everyone can join in! Learn more: bit.ly/stayinhealthca… 2/4
So nice to see a new agent be added for neoadjuvant for TNBC
FDA has approved pembrolizumab as neoadjuvant➡️adjuvant therapy for pts w/ high-risk early-stage triple neg #breastcancer (#TNBC) after KN522 met co-primary endpts. New indication in 📸. See Sect 14.18 of label for info: bit.ly/3f1syXr. Great news for #bcsm! #OncTwitter
D?
FDA has approved pembrolizumab as neoadjuvant➡️adjuvant therapy for pts w/ high-risk early-stage triple neg #breastcancer (#TNBC) after KN522 met co-primary endpts. New indication in 📸. See Sect 14.18 of label for info: bit.ly/3f1syXr. Great news for #bcsm! #OncTwitter
United States トレンド
- 1. $TCT 1,544 posts
- 2. Cyber Monday 30.1K posts
- 3. Good Monday 35K posts
- 4. #MondayMotivation 6,882 posts
- 5. TOP CALL 11K posts
- 6. #IDontWantToOverreactBUT N/A
- 7. #MondayVibes 2,985 posts
- 8. #NavidadConMaduro 1,454 posts
- 9. Victory Monday N/A
- 10. New Month 391K posts
- 11. Clarie 2,495 posts
- 12. Rosa Parks 2,815 posts
- 13. #MondayMood 1,238 posts
- 14. John Denver 1,583 posts
- 15. Happy 1st 24.4K posts
- 16. Jillian 1,940 posts
- 17. Alina Habba 7,641 posts
- 18. Luigi Mangione 2,343 posts
- 19. Bienvenido Diciembre 3,122 posts
- 20. Merry Christmas 33.6K posts
おすすめツイート
Something went wrong.
Something went wrong.